OceansBio오션스바이오

OceansBio shares have fallen sharply over the past year, and a new rights offering decision was filed in October 2026.

OceansBio is a small KONEX-listed medical device maker focused on electroceuticals, devices that use electrical or magnetic stimulation to treat conditions such as epilepsy and depression. The share price closed at ₩2,700 on 2026-10-20, down 46% over one year, with a market capitalisation of about ₩4.0B. The data provided contains no trailing financials, annual results or valuation multiples, so the current financial position cannot be assessed from this pack.

What stands out

• The share price is down 46% over one year and 10.4% over one month, though it is roughly flat over three months.
• The most recent filing is a rights offering (paid-in capital increase) decision dated 2026-10-14, following earlier amended versions of rights offering decisions in March and April 2026.
• Several filings relate to share issuances, including a third-party allotment of redeemable convertible preferred stock in March 2026, which may bear on dilution.
• Institutional investors were net buyers over the last 20 days while retail investors were net sellers by a similar amount; foreign ownership is 0%.
• No news headlines were available, and financial statements, annual results and valuation ratios are not included in the data.

What to watch

• Terms and size of the rights offering from the October 2026 decision, and how it could affect the share count and dilution.
• Next filings on the amended annual report for December 2025 and any updated financial statements, since the data has none.
• Share price is well below its 52-week high of ₩7,930, and the data does not explain the reasons for the decline.